Hepatitis B virus (HBV) infection has been a major global cause of morbidity and mortality. The recognition of the problem led to a worldwide effort to reduce transmission of HBV through routine infant vaccination. HBV infection is the most common cause of chronic liver diseases and hepatocellular carcinoma in Korea. After hepatitis B vaccine era, seroprevalence of hepatits B surface antigen is decreasing, particularly in children. Hepatitis B vaccine is remarkably safe and shows high immunogenicity. Universal childhood immunization with three doses of hepatitis B vaccine in the first year of life is a highly effective method for prevention and control of hepatitis B. (Korean J Hepatol 2011;17:87-95)
INTRODUCTION
Hepatitis B is an infectious disease, associated with an estimated 350 million chronically infected patients. 1 Perinatal transmission is an important cause of hepatitis B virus (HBV) transmission, account for 35% to 50% of HBV carriers. 2 Korea is an endemic area of HBV infection, therefore, hepatitis B is an important public health problem.
This review describes an overview of HBV infection, epidemiology, immunization, and prevention.
HEPATITIS B VIRUS
HBV is a 42-nm DNA virus in the family Hepadnaviridae.
The virus has a partially double-stranded DNA with core antigen surrounded by a shell containing surface antigen (HBsAg). 3 HBV contains numerous antigenic components, including HBsAg, HBcAg, and hepatitis B e antigen (HBeAg). The HBV genome has 3200 nucleotides, and it efficiently uses its genetic information to encode four groups of proteins and their regulatory elements by shifting the reading frames over the same genetic material. 4 The immune response to HBsAg provides the immunity against HBV. 
MODE OF TRANSMISSION
HBV is transmitted parenterally by contaminated blood or other body fluids through blood vessels, skin or mucous membranes. The virus can be detected in all human body fluids, the virus concentration in the fluids is highest in the blood or serous exudates, and it is relatively low in saliva, semen, vaginal fluids. 5 Thus, there is almost no risk of transmission in the course of daily life, and the infection through fecal-oral transmission does not occur.
The main transmission routes include perinatal infection, the skin and mucous membrane infections caused by contaminated blood or body fluids (blood transfusion, use of contaminated syringes, hemodialysis, invasive tests or surgery), and sexual contacts. In Korea, the most important route is perinatal transmission in patients with chronic hepatitis B. respectively, of which 90% will progress to chronic infection. 7, 8 When given with vaccine and immunoglobulin within 24 hours after birth, 90% of infants show the preventive effect. 9 Although a very small amount of HBV is detected in breast milk, there is no evidence that hepatitis B is transmitted through breast milk.
In injection drug abuser, using the same syringe among injection drug users at the same time is the main transmission route of hepatitis B infection. 10 In addition, tattooing, ear piercing, acupuncture, dialysis, and even using a syringe can be the source of infection.
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In adolescents and adults in the countries with low and middle prevalence rates of hepatitis B, sexual contact is the major cause of HBV infection. 12 Recently, as the prevalence of HBV infection is decreasing in young adult age group in Korea, the sexual contact has become the main transmission route. 10 years old, to about 1.6% in the teens, and also it was reduced to 3% in the early 20s. 27 However, the prevalenc rate in 20s and over showed 7.6% in men and 3.4% in women, respectively, indicating no significant differences to the prevalence rates in the past. Perinatal infection in HBV carriers was also as high as 54.7% in age 20 and over, while it was reduced to 7.4% in age less than 10. 28 Hepatitis B vaccine has been included in a National Immunization
CLINICAL FEATURES
Program, and since 95% of infants are vaccinated, the neonatal hepatitis B prevention in Korea is being implemented effectively. 29 Recently, the HBsAg positive rate for those under school age is very low at less than 1%. 30 Twenty years after the introduction of the vaccine, the prevalence of HBV infection is decreasing in adolescence and young adults as well as in the ages of infants and children. A nationwide sero-epidemiological survey is needed to provide immunization strategies in adult population.
The occurrence of acute hepatitis B also decreased, and in recent years, it became rarely observed in age groups under 20. 31 The phenomenon of the decrease in young patients with acute hepatitis B is similar to other countries such as Taiwan or the United States, and it is consistent with the time for introduction of hepatitis B vaccination. [32] [33] [34] The reduced incidence of acute hepatitis B in youth ultimately implies the reduced incidence of acute hepatitis B infection for the society or country as a whole. On the other hand, the incidence of acute hepatitis B in the age group over 30 years is relatively high compared to the younger age groups, which might be due to many unvaccinated people. 31 
EFFICACY OF HEPATITIS B VACCINE
The The antibody response to hepatitis B vaccine is 90% in healthy adults and 95% of infants, children, and adolescents. 36 As for vaccine efficacy, complete protection has been achieved among immunocompetent persons who developed anti-HBs titers of 10 mIU/mL or greater after completion of vaccination. 35, 37 Long-term follow-up studies of newborn vaccination demonstrated that antibodies become negative in 15-50% among the vaccine responders within 5 to 10 years. 33, 38, 39 In adults, antibodies become negative in 7-50% within 5 years, and 30-60% within 10 years. 39, 40 In the cohort study for 20 years after infant vaccination, booster vaccination in cases of waning antibody produced antibody response rate in excess of 80%, and HBV infection did not occur during the period of the cohort. 41 The persistent protection against clinically significant hepatitis B despite of declining antibody titers is an anamnestic immune response after HBV exposure. 42 This indicates that the immune system would be Further vaccination of the nonresponders administered in the deltoid muscle produces adequate antibody response in 15% to 25% of them after one additional dose and in 30% to 50% after three additional doses. 48 There are several approaches to improve the antibody response to vaccine. Obesity can be a major cause of lowering the rate of antibody production by the vaccine, recently it has been reported that antibody titers were raised by using long needles. 49 The research for developing new vaccines to improve immunity of the vaccine also has been actively conducted. The vaccines including the Pre-S antigen produced by recombinant DNA methods using CHO cells, only about 3% of HBV infection rate, and it has been decreased less than 1% in children. 27 The incidence of acute hepatitis B has been also reduced, therefore, the incidence of chronic liver diseases or hepatocellular carcinoma by HBV infection could be expected to decrease in the future. Chinese Hamster Ovary cell). 58 Antibody conversion rates and geometric means of the generated antibody titers by recombinant vaccines are similar to the plasma vaccines. Vaccination shall be given at 0, 1, and 6-month intervals.
A second vaccination shall be given at one month after the first vaccination, and in case of missing the vaccination schedule, without having to start again, it shall be given right away, and a third vaccination shall be given at the interval of two months or more after second vaccination.
Storage and safety of vaccines
Most hepatitis B vaccines should be kept in 2-8℃ storage temperatures, and the efficacy is maintained at least 4 years.
Vaccine efficacy is maintained at room temperature and can be stored for up to one year. Vaccine should not be frozen because the freezing causes the HbsAg protein to dissociate from the alum adjuvant and lose immungenicity. 
Vaccine non-responder
Anti-HBs response less than 10 mIU/mL after completion of the first vaccine series is called 'nonresponders'.
Re-vaccination is recommended in the nonresponders.
Administration of a single dose of vaccine, followed by measurement of anti-HBs antibody response 1-3 months later to differentiate anamnestic response. For persons who are seronegative after the booster dose, a second vaccine series of two additional doses, which result in seroconversion in 50 to 60% of recipients. 48 Generally, additional vaccination is not recommended to the complete nonresponders who do not achieve the appropriate antibody level even after a total of 6 times of vaccinations. HBIG should be administered when they are exposed to HBV.
Adverse reactions
Hepatitis B vaccine is safe and mild side effects appear within 24 hours, showing fever in 1-6%, injection site pain in 3-29%, redness and mild swelling in 3%, and headache in 3%. 63, 64 Arthritis, multiple sclerosis, diabetes, Guillain-Barre syndromes have no direction association to the hepatitis B vaccination. 65 Hypersensitivity to vaccine components, such as yeast, can cause anaphylaxis. 66 
Indications
Comprehensive HBV immunization strategies prevent chronic HBV infection acquired in all age groups. In the past, vaccination to all newborns was performed mainly in the hepatitis B prevalent areas, but since 1997, hepatitis B The vaccine can be given to immunocompromised patients, but the antibody response to the vaccination is lower than in healthy people. (Table 2 ). In nonresponders, restart the vaccination after the injection of HBIG immediately.
In nonresponders who did not complete re-vaccination after the primary vaccination, it is better to start again after 1 time of HBIG injection. In nonresponders even after 3 times of re-vaccination, it is preferred to perform 2 times of HBIG injection.
General measures
HBV is mainly transmitted through perinatal infection, sexual contact, blood, and contaminated needles from drug abusers. It can be transmitted through the direct contacts or skin wounds between patients and surgeons or dentists, or indirectly through hemodialysis, razors, toothbrushes, and acupuncture therapy. 32 including Korea. We also should pay attention to the prevention of perinatal transmission and HBV infection in unvaccinated adults.
